Breaking News Instant updates and real-time market news.

CLLS

Cellectis

$16.86

-0.76 (-4.31%)

, FMS

Fresenius Medical

$38.96

-0.45 (-1.14%)

07:43
12/01/16
12/01
07:43
12/01/16
07:43

Deutsche Bank to hold a conference

Pharmaceutical & Healthcare Corporate Day is being held in London, England on December 1.

CLLS

Cellectis

$16.86

-0.76 (-4.31%)

FMS

Fresenius Medical

$38.96

-0.45 (-1.14%)

AZN

AstraZeneca

$26.14

-0.57 (-2.13%)

NVS

Novartis

$68.76

-0.2 (-0.29%)

NVO

Novo Nordisk

$33.60

0.88 (2.69%)

RHHBY

Roche

$27.76

-0.05 (-0.18%)

  • 01

    Dec

  • 03

    Dec

  • 03

    Dec

  • 07

    Dec

  • 16

    Feb

CLLS Cellectis
$16.86

-0.76 (-4.31%)

11/23/16
PIPR
11/23/16
NO CHANGE
PIPR
Piper says CAR-T researchers must heed risks highlighted by Juno news
Piper Jaffray analyst Joshua Schimmer said the CAR-T field has "taken another step back" after Juno Therapeutics (JUNO) put a hold on its JCAR015 trial again due to fatal cerebral edema and cautioned companies exploring these therapies to be mindful of "unnecessarily aggressive development and under-appreciation of the potent and possibly highly toxic nature" of the approach. However, Schimmer expressed his confidence that companies he covers in the CAR-T space - namely bluebird bio (BLUE), Cellectis (CLLS), Celgene (CELG), Bellicum Pharmaceuticals (BLCM), Lion Biotechnologies (LBIO) and NantKwest (NK) - will "respect the power of these platforms and remember patients' lives are more important than stock prices."
10/27/16
LTCO
10/27/16
NO CHANGE
Target $45
LTCO
Buy
Cellectis recent selloff unwarranted, says Ladenburg
Ladenburg Thalmann analyst Wangzhi Li says the recent pullback in shares of Cellectis is unwarranted. The UCART19 Phase 1 trial is dosing patients on schedule, which is a positive sign for the outcome readout of the trial, Li tells investors in a research note. The analyst recommends buying the shares on the pullback and keeps a Buy rating on the name with a $45 price target.
04/05/16
LTCO
04/05/16
INITIATION
Target $45
LTCO
Buy
Cellectis initiated with a Buy at Ladenburg
Ladenburg Thalmann analyst Wangzhi Li started Cellectis with a Buy rating and $45 price target.
08/31/16
PIPR
08/31/16
NO CHANGE
PIPR
Piper's Schimmer unsure of impact from Novartis CAR-T shakeup
Piper Jaffray analyst Joshua Schimmer said he's struggling with the implications of the news that Novartis (NVS) is reportedly eliminating its Cell and Gene Therapy unit as a stand-alone entity, which is primarily focused on development of CAR-T and adoptive immunotherapies. On the one hand, removing a leading competitor is a positive for the rest of the field, Schimmer tells investors in a research note. On the other hand, the move by Novartis could signal "significant challenges" in the field, the analyst adds. Schimmer continues to prefer companies "with unique and differentiated approaches," namely Bellicum Pharmaceuticals (BLCM), Cellectis (CLLS), Lion Biotechnologies (LBIO), Amgen (AMGN), Celgene (CELG) and bluebird bio (BLUE). Juno Therapeutics (JUNO) and Kite Pharma (KITE) are down 6% and 5%, respectively, in midday trading.
FMS Fresenius Medical
$38.96

-0.45 (-1.14%)

10/13/16
RHCO
10/13/16
NO CHANGE
RHCO
Price targets cut on dialysis stocks at SunTrust
SunTrust analyst David MacDonald lowered his price targets on dialysis stocks, citing CMS' recent request for information and resulting payor risk and lower assumed multiples. The analyst cut his price target on American Renal Associates (ARA) to $24 from $34, on DaVita (DVA) to $66 from $80 and on Fresenius Medical (FMS) to $48 from $54. He maintains Buy ratings on American Renal and Fresenius but said he does not expect the stocks to rise significantly until the CMS matter is resolved. MacDonald keeps a Hold rating on DaVita.
09/06/16
SBSH
09/06/16
INITIATION
SBSH
Buy
Fresenius Medical initiated with a Buy at Citi
Price target EUR 98.
09/06/16
SBSH
09/06/16
INITIATION
Target $71
SBSH
Neutral
DaVita initiated with a Neutral at Citi
Citi analyst Patrick Wood started DaVita Healthcare Partners (DVA) with a Neutral rating and $71 price target. The analyst sees limited upside to consensus estimates and prefers Fresenius Medical Care (FMS) at current share levels.
07/08/16
JEFF
07/08/16
UPGRADE
JEFF
Hold
Fresenius Medical upgraded to Hold from Underperform at Jefferies
Jefferies analyst Chris Cooper upgraded Fresenius Medical to Hold with a EUR 81 price target.
AZN AstraZeneca
$26.14

-0.57 (-2.13%)

11/09/16
SBSH
11/09/16
NO CHANGE
SBSH
Citi sees Healthcare 'relief rally' after Trump win
Citi analyst Andrew Baum expects a "'relief rally" to drive near-term sector outperformance for names in the Healthcare space given the "inability of the Democrats to attain the Presidency, the House or Congress." Longer term, however, the analyst still sees "significant continued legislative risk" for pharma reimbursement. Baum prefers GlaxoSmithKline (GSK), AstraZeneca (AZN), Shire (SHPG) and Roche (RHHBY) among European majors and Bristol-Myers (BMY) and Eli Lilly (LLY) in the U.S.
10/26/16
PIPR
10/26/16
NO CHANGE
PIPR
Neutral
Piper still uncertain on Clovis position after AstraZeneca data
AstraZeneca's (AZN) Phase III study of Lynparza in ovarian cancer "substantially improved" progression-free survival over what was seen in study 19, suggesting a profile at least similar to TESARO's (TSRO) niraparib, Piper Jaffray analyst Steven Breazzano tells investors in a research note. The new data confirm that the various PARP inhibitors are more similar than different, which bodes well for Clovis Oncology's (CLVS) own maintenance study, the analyst contends. Breazzano, however, remains the sidelines with respect to Clovis shares given the "increasingly competitive dynamic" in ovarian cancer and uncertainty in the company's position in the important maintenance setting. The analyst keeps a Neutral rating on Clovis.
11/28/16
SBSH
11/28/16
DOWNGRADE
Target $60
SBSH
Neutral
Citi analyst 'perturbed,' downgrades AbbVie to Neutral
Citi analyst Andrew Baum earlier today downgraded AbbVie (ABBV) to Neutral from Buy and lowered his price target for the shares to $60 from $65. The biopharmaceutical company is trading down 2%, or 99c, to $59.52. The risk to post 2017 consensus estimates for Humira has "increased on almost all fronts," Baum tells investors in a research note. The analyst sees increased patent risk and competition from biosimilar Enbrel in Europe. He also believes AstraZeneca (AZN) and Acerta's acalabrutinib "looks like a better mousetrap" than AbbVie's Imbruvica. Baum is also "perturbed" by AbbVie management's recent "rich" acquisition of Stemcentrx. He prefers shares of Eli Lilly (LLY) and Bristol-Myers (BMY) to AbbVie.
10/20/16
JANY
10/20/16
NO CHANGE
Target $1.5
JANY
Neutral
Cerulean cash infusion gives chance to execute on programs, says Janney Capital
Janney Capital analyst Debjit Chattopadhyay said Cerulean's (CERU) collaboration with Novartis (NVS), which comes with a "modest" $5M upfront payment, and its $20M ATM facility with Aspire Capital, while "not ideal," gives management a chance to execute on three of its ongoing programs, the most important of which is the dose escalation study with Olaparib with partner AstraZeneca (AZN) that should have preliminary data in 2Q17. The analyst raised his fair value estimate on Cerulean to $1.50 from $1.00 and keeps a Neutral rating on the stock.
NVS Novartis
$68.76

-0.2 (-0.29%)

11/10/16
ARGS
11/10/16
UPGRADE
ARGS
Buy
Novartis upgraded to Buy from Hold at Argus
10/26/16
LEER
10/26/16
NO CHANGE
Target $80
LEER
Market Perform
Novartis price target lowered to $80 from $89 at Leerink
Leerink analyst Seamus Fernandez lowered his price target for Novartis to $80 from $89 after a "disappointing" Q3 performance despite bottom-line beat. The analyst reiterates a Market Perform rating on the shares.
11/10/16
11/10/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Priceline (PCLN) upgraded to Buy from Hold at Stifel while the firm upgraded Expedia (EXPE) to Hold from Sell. 2. IBM (IBM) upgraded to Buy from Neutral at BofA/Merrill with analyst Wamsi Mohan expecting 2017 profits to grow as earnings have stabilized and negative revisions are unlikely and expects tailwinds from moderating pace of investments and savings from restructuring efforts. 3. L-3 Communications (LLL) and Northrop Grumman (NOC) upgraded to Overweight from Equal Weight at Barclays while the firm upgraded Lockheed Martin (LMT) to Equal Weight from Underweight. 4. Microsoft (MSFT) upgraded to Neutral from Underweight at Atlantic Equities. 5. Novartis (NVS) upgraded to Buy from Hold at Argus. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/30/16
RHCO
11/30/16
NO CHANGE
RHCO
GlycoMimetics has positive read through from deal, says SunTrust
SunTrust analyst Yatin Suneja says that Novartis' (NVS) recent acquisition of Selexys Pharmaceuticals "provides further clinical and commercial validation for the selectin class of adhesion molecules as meaningful therapeutic targets." The analyst notes that the acquisition came after Selexys' SelG1, which utilizes a P-selectin antibody, showed positive Phase II data in sickle cell disease. GlycoMimetics (GLYC) develops selectin antagonists. The analyst expects interest in the name to accelerate as more data is announced. Suneja keeps a Buy rating on the shares.
NVO Novo Nordisk
$33.60

0.88 (2.69%)

09/23/16
PIPR
09/23/16
INITIATION
PIPR
Neutral
Novo Nordisk initiated with a Neutral at Piper Jaffray
Piper Jaffray analyst Richard Purkiss started Novo Nordisk with a Neutral rating and DKK 320 price target.
09/13/16
EXAN
09/13/16
UPGRADE
EXAN
Outperform
Novo Nordisk upgraded to Outperform from Neutral at Exane BNP Paribas
10/31/16
SBSH
10/31/16
DOWNGRADE
SBSH
Neutral
Novo Nordisk downgraded to Neutral from Buy at Citi
Citi analyst Peter Verdult downgraded Novo Nordisk to Neutral citing the ongoing net pricing declines across the company's diabetes portfolio as well as expectations for margin erosion at Biopharmaceuticals due to NovoSeven/Norditropin pressures. The analyst cut his price target for the shares to DKK 260 from DKK 400.
10/28/16
BOFA
10/28/16
DOWNGRADE
BOFA
Underperform
Novo Nordisk downgraded to Underperform from Neutral at BofA/Merrill
RHHBY Roche
$27.76

-0.05 (-0.18%)

09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
10/19/16
LEER
10/19/16
NO CHANGE
LEER
Roche Tecentriq approval increases competition, says Leerink
Leerink analyst Seamus Fernandez says that the FDA approval of Roche's (RHHBY) Tecentriq in second-line non-small cell lung cancer patients regardless of PD-L1 expression comes as no surprise given its previously reported overall survival advantage. Nonetheless, the analyst believes it creates new competition for Bristol-Myers' (BMY) Opdivo and Merck's (MRK) Keytruda in this setting.
09/12/16
JEFF
09/12/16
NO CHANGE
Target $57
JEFF
Hold
Jefferies cuts Bristol-Myers price target, upgrades AstraZeneca
Jefferies analyst Jeffrey Holford lowered his price target for Bristol-Myers Squibb (BMY) to $57 from $69 saying the stock is positioned for a "rough mid term ride." The analyst sees a "difficult catalyst" set for Bristol shares with "numerous" upcoming competitor read-outs in non-small cell lung cancer. The market could see worse than expected data from Bristol's CM-026 and CM-568 studies as well as better than expected data from AstraZeneca's (AZN) MYSTIC study and Roche's (RHHBY) Chemo-IO studies in the first half of 2017, Holford tells investors in a research note. He keeps a Hold rating on Bristol and upgraded this morning AstraZeneca to Buy from Hold. Holford prefers Astra for its immunology exposure.

TODAY'S FREE FLY STORIES

GPMT

Granite Point Mortgage

09:43
06/23/17
06/23
09:43
06/23/17
09:43
Syndicate
Breaking Syndicate news story on Granite Point Mortgage »

Granite Point Mortgage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

MDSO

Medidata

$80.25

4.25 (5.59%)

09:42
06/23/17
06/23
09:42
06/23/17
09:42
Conference/Events
Medidata management to meet with Piper Jaffray »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 28

    Jun

  • 29

    Jun

  • 11

    Jul

LPI

Laredo Petroleum

09:41
06/23/17
06/23
09:41
06/23/17
09:41
Conference/Events
Laredo Petroleum management to meet with Piper Jaffray »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 28

    Jun

IFF

International Flavors

09:41
06/23/17
06/23
09:41
06/23/17
09:41
Hot Stocks
International Flavors to settle trade secret lawsuit with ZoomEssence for $56M »

ZoomEssence and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPMT

Granite Point Mortgage

09:40
06/23/17
06/23
09:40
06/23/17
09:40
Syndicate
Granite Point Mortgage indicated to open at $18-$19, IPO priced at $19.50 »

Granite Point Mortgage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

LGF.A

Lionsgate

09:40
06/23/17
06/23
09:40
06/23/17
09:40
Conference/Events
Lionsgate management to meet with B. Riley »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

NGD

New Gold

, GILD

Gilead

$70.48

2.98 (4.41%)

09:40
06/23/17
06/23
09:40
06/23/17
09:40
Options
Unusually active option classes on open June 23rd »

Unusual total active…

NGD

New Gold

GILD

Gilead

$70.48

2.98 (4.41%)

ORCL

Oracle

VRX

Valeant

AMD

AMD

$14.38

0.4 (2.86%)

DIS

Disney

SLV

iShares Silver Trust

CAT

Caterpillar

COST

Costco

$159.79

-3.36 (-2.06%)

TWTR

Twitter

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 06

    Jul

  • 19

    Jul

  • 08

    Aug

  • 23

    Aug

  • 24

    Aug

  • 29

    Aug

STML

Stemline

$8.50

0.15 (1.80%)

09:39
06/23/17
06/23
09:39
06/23/17
09:39
Hot Stocks
Stemline presents updated stage 1 and 2 data from SL-401 trial »

Stemline Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 26

    Sep

LGF

Use LGF.A, LGF.B

09:39
06/23/17
06/23
09:39
06/23/17
09:39
Conference/Events
Use LGF.A, LGF.B management to meet with B. Riley »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

INN

Summit Hotel Properties

09:38
06/23/17
06/23
09:38
06/23/17
09:38
Conference/Events
Summit Hotel Properties management to meet with Canaccord »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 13

    Jul

IMGN

ImmunoGen

$5.82

-0.2 (-3.32%)

09:38
06/23/17
06/23
09:38
06/23/17
09:38
Conference/Events
ImmunoGen management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 28

    Jun

REGN

Regeneron

$526.53

4.51 (0.86%)

09:36
06/23/17
06/23
09:36
06/23/17
09:36
Hot Stocks
Breaking Hot Stocks news story on Regeneron »

Regeneron down 4.6% to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ETSY

Etsy

$14.68

0.48 (3.38%)

09:36
06/23/17
06/23
09:36
06/23/17
09:36
Periodicals
Several private equity firms have reached out to Etsy, Dealreporter says »

While Etsy has not been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAT

Caterpillar

09:36
06/23/17
06/23
09:36
06/23/17
09:36
Technical Analysis
Technical View: Caterpillar slips lower, analyst action »

Shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HQY

HealthEquity

$51.05

-0.39 (-0.76%)

09:36
06/23/17
06/23
09:36
06/23/17
09:36
Conference/Events
HealthEquity management to meet with Barrington »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

APLP

Archrock Partners LP

$13.66

0.61 (4.67%)

09:35
06/23/17
06/23
09:35
06/23/17
09:35
Downgrade
Archrock Partners LP rating change  »

Archrock Partners LP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:35
06/23/17
06/23
09:35
06/23/17
09:35
General news
U.S. new home sales preview: »

U.S. new home sales…

AROC

Archrock

09:34
06/23/17
06/23
09:34
06/23/17
09:34
Downgrade
Archrock rating change  »

Archrock downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WRE

Washington REIT

09:32
06/23/17
06/23
09:32
06/23/17
09:32
Conference/Events
Washington REIT management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

  • 28

    Jul

  • 27

    Oct

09:30
06/23/17
06/23
09:30
06/23/17
09:30
General news
PMI Composite Flash â€' Level to be reported at 09:45 »

June PMI Composite Flash…

09:30
06/23/17
06/23
09:30
06/23/17
09:30
General news
PMI Composite Flash Manufacturing â€' Level to be reported at 09:45 »

June PMI Composite Flash…

ADHD

Alcobra

, AVEO

AVEO Oncology

$0.73

0.0281 (4.02%)

09:29
06/23/17
06/23
09:29
06/23/17
09:29
Hot Stocks
On The Fly: Pre-market Movers »

HIGHER: Alcobra (ADHD),…

ADHD

Alcobra

AVEO

AVEO Oncology

$0.73

0.0281 (4.02%)

SNCR

Synchronoss

$12.18

1.53 (14.37%)

BBRY

BlackBerry

$11.06

0.41 (3.85%)

BBBY

Bed Bath & Beyond

$33.74

0.08 (0.24%)

BLCM

Bellicum Pharmaceuticals

$13.98

1.33 (10.51%)

BLUE

bluebird bio

$118.50

-1.8 (-1.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 23

    Jun

  • 23

    Jun

  • 29

    Jun

  • 26

    Sep

RIO

Rio Tinto

, GLNCY

Glencore

$7.10

0.05 (0.71%)

09:29
06/23/17
06/23
09:29
06/23/17
09:29
Hot Stocks
Glencore raises offer for Rio Tinto's Coal & Allied to $2.675B plus royalties »

Glencore (GLNCY)…

RIO

Rio Tinto

GLNCY

Glencore

$7.10

0.05 (0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALGN

Align Technology

$149.69

0.27 (0.18%)

09:28
06/23/17
06/23
09:28
06/23/17
09:28
Conference/Events
Stifel medical technology analysts hold an analyst/industry conference call »

Research Team discusses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 26

    Jun

PAAS

Pan American Silver

$16.95

0.51 (3.10%)

09:28
06/23/17
06/23
09:28
06/23/17
09:28
Conference/Events
Pan American Silver management to meet with JPMorgan »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.